We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A District of Columbia federal court ruled Mylan Pharmaceuticals and two chemical companies must pay $67 million to Blue Cross Blue Shield of Massachusetts and three other insurers in a long-running suit that accused the companies of antitrust violations. Read More
The FDA approved Gazyva for the treatment of patients with follicular lymphoma who relapsed after, or are resistant to, a rituximab-containing regimen. Read More
The FDA cited multiple problems with labeling claims at a Phoenix manufacturer that specializes in colostrum, the milk produced by maternal mammals immediately after giving birth. Read More
A mutual fund, citing $80 billion in losses on its investment in drugmaker Valeant, filed a lawsuit alleging securities violations, mail and wire fraud, and violations of the Racketeer Influenced and Corrupt Organizations Act (RICO). Read More
A Georgia compounding pharmacy ran afoul of the FDA after losing the exemption from agency rules that is extended to compounders that limit their production to filling prescriptions for individual patients, the FDA said in a warning letter. Read More